论文部分内容阅读
目的:研究CD26+表型卵巢癌SKOV-3细胞体外侵袭能力。方法:利用免疫荧光标记物流式分选法(FACS)分选SKOV-3细胞系中CD26+表型细胞,并利用transwell小室进行体外侵袭实验检测CD26+及CD26-表型细胞侵袭能力。结果:SKOV-3细胞系中存在CD26+表型细胞,占7.3%,CD26-细胞占92.7%;CD26+细胞侵袭过人工基底膜细胞数为111.5±7.27,CD26-细胞侵袭过人工基底膜细胞数为60.2±5.53,CD26+亚群细胞穿过人工基底膜细胞数强于CD26-细胞亚群,差异有统计学意义(P<0.05)。结论:SKOV-3细胞系中存在CD26+表型细胞,且CD26+表型细胞侵袭能力强于CD26-细胞,提示CD26可能作为卵巢癌干细胞标志物并成为卵巢癌抗转移的新靶点。
Objective: To investigate the in vitro invasiveness of CD26 + phenotype ovarian cancer SKOV-3 cells. Methods: CD26 + phenotype cells in SKOV-3 cell line were sorted by immunofluorescence labeling and flow cytometry (FACS). The invasion ability of CD26 + and CD26- phenotype cells was detected by transwell chamber in vitro. Results: There were 7.3% of CD26 + phenotype cells in SKOV-3 cell line, 92.7% of CD26- cells in SKOV-3 cell line, 111.5 ± 7.27 in invasive human basement membrane cells in CD26 + cell line, 60.2 ± 5.53. The number of CD26 + subpopulation cells crossing the artificial basement membrane was stronger than that of CD26- cell subpopulation, with significant difference (P <0.05). Conclusion: CD26 + phenotype cells exist in SKOV-3 cell line, and CD26 + phenotype cells are more invasive than CD26- cells, suggesting that CD26 may serve as a marker of ovarian cancer stem cells and become a new target of ovarian cancer anti-metastasis.